Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

GlobeNewswire August 11, 2022

Medicenna (TSX:MDNA) prices US$20 million public offering

Trevor Abes  August 9, 2022

Medicenna Announces Pricing of US$20 Million Public Offering of Units

GlobeNewswire August 9, 2022

Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

GlobeNewswire August 8, 2022

Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022

GlobeNewswire August 5, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11's Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

GlobeNewswire July 27, 2022

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

GlobeNewswire June 22, 2022

Medicenna (TSX:MDNA) strengthens IP protection for Superkine platform with U.S. patent

Azuka Onwuka June 9, 2022

Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

GlobeNewswire June 9, 2022

Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022

GlobeNewswire June 7, 2022

Medicenna (TSX:MDNA) presents Phase 1/2 ABILITY study data

Brieanna McCutcheon  May 11, 2022

Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11's Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting

GlobeNewswire May 11, 2022

Medicenna (TSX:MDNA) MDNA11 showing stimulation of anti-cancer immune cells

Caroline Egan  May 2, 2022

Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study

GlobeNewswire May 2, 2022

Medicenna Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 27, 2022

Medicenna (TSX:MDNA)shares preclinical data highlighting the efficacy of Anti-PD1-IL-2 BiSKIT

John Ballem  April 8, 2022

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

GlobeNewswire April 8, 2022

Medicenna Presents Preclinical Data Demonstrating Anti-Cancer Activity of a Long-Acting IL-13 Super-Antagonist at the AACR Annual Meeting

GlobeNewswire April 8, 2022

Medicenna Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire March 10, 2022

Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting

GlobeNewswire March 9, 2022